Treatment of inclusion body myositis: Is low-dose intravenous immunoglobulin the solution?

Rheumatology International

Volumn 32, Issue 2, 2012, Pages 469-472

  Recher, Mike ^a   Sahrbacher, Ulrike ^a   Bremer, Juliane ^b   Arndt, Börge ^a   Steiner, Urs ^a   Fontana, Adriano ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

IBM; Inclusion body myositis; IVIG; Low dose IVIG; Myositis

Indexed keywords

AZATHIOPRINE; CREATINE KINASE; IMMUNOGLOBULIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PREDNISONE;

AGED; ARTICLE; CASE REPORT; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INCLUSION BODY MYOSITIS; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE BIOPSY; MUSCLE WEAKNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; AGED; AZATHIOPRINE; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MUSCLE, SKELETAL; MYOSITIS, INCLUSION BODY; TREATMENT OUTCOME;

EID: 84857055219     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-009-1290-z     Document Type: Article

References (18)

1. MC Dalakas 1991 Polymyositis, dermatomyositis and inclusion-body myositis N Engl J Med 325 21 1487 1498 1658649 10.1056/NEJM199111213252107 1:STN:280:DyaK38%2FkvFGltQ%3D%3D
2. RC Griggs 2006 The current status of treatment for inclusion-body myositis Neurology 66 2 Suppl 1 S30 S32 16432142
3. M Needham FL Mastaglia 2007 Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches Lancet Neurol 6 7 620 631 17582362 10.1016/S1474-4422(07)70171-0 (Pubitemid 46921056)
4. MC Dalakas B Sonies J Dambrosia E Sekul E Cupler K Sivakumar 1997 Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study Neurology 48 3 712 716 9065553 1:STN:280: DyaK2s3hslyqsA%3D%3D (Pubitemid 27120112)
5. MC Walter H Lochmuller M Toepfer B Schlotter P Reilich M Schroder, et al. 2000 High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study J Neurol 247 1 22 28 10701893 10.1007/s004150050005 1:STN:280:DC%2BD3c7mtlyhug%3D%3D (Pubitemid 30162508)
6. D Pongratz 2006 Therapeutic options in autoimmune inflammatory myopathies (dermatomyositis, polymyositis, inclusion body myositis) J Neurol 253 Suppl 5 V64 V65 16998756 10.1007/s00415-006-5010-2 (Pubitemid 44441157)
7. M Wittstock R Benecke UK Zettl 2003 Therapy with intravenous immunoglobulins: complications and side-effects Eur Neurol 50 3 172 175 14530624 10.1159/000073059 1:CAS:528:DC%2BD3sXnvV2is7Y%3D (Pubitemid 37256053)
8. P Imbach S Barandun V d'Apuzzo C Baumgartner A Hirt A Morell, et al. 1981 High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood Lancet 1 8232 1228 1231 6112565 10.1016/S0140-6736(81)92400-4 1:STN:280:DyaL3M7ps1Cjtw%3D%3D
9. JB Bussel RP Kimberly RD Inman I Schulman C Cunningham-Rundles N Cheung, et al. 1983 Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura Blood 62 2 480 486 6191803 1:STN:280: DyaL3s3lslOqtQ%3D%3D (Pubitemid 13036102)
10. A Samuelsson TL Towers JV Ravetch 2001 Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor Science 291 5503 484 486 11161202 10.1126/science.291.5503.484 1:CAS:528:DC%2BD3MXlslensw%3D%3D (Pubitemid 32097072)
11. Y Kaneko F Nimmerjahn JV Ravetch 2006 Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation Science 313 5787 670 673 16888140 10.1126/science.1129594 1:CAS:528:DC%2BD28Xnsl2hsbY%3D (Pubitemid 44201145)
12. RM Anthony F Nimmerjahn DJ Ashline VN Reinhold JC Paulson JV Ravetch 2008 Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc Science 320 5874 373 376 18420934 10.1126/science.1154315 1:CAS:528: DC%2BD1cXks1GhsLs%3D (Pubitemid 351555659)
13. RM Anthony F Wermeling MC Karlsson JV Ravetch 2008 Identification of a receptor required for the anti-inflammatory activity of IVIG Proc Natl Acad Sci USA 105 50 19571 19578 19036920 10.1073/pnas.0810163105 1:CAS:528: DC%2BD1cXhsFCltr%2FI
14. MC Dalakas 2006 The role of high-dose immune globulin intravenous in the treatment of dermatomyositis Int Immunopharmacol 6 4 550 556 16504918 10.1016/j.intimp.2005.11.016 1:CAS:528:DC%2BD28Xhslyrs78%3D
15. S Barbasso Helmers M Dastmalchi H Alexanderson I Nennesmo M Esbjornsson B Lindvall, et al. 2007 Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies Ann Rheum Dis 66 10 1276 1283 17277004 10.1136/ard.2006.058644 (Pubitemid 47492468)
16. A Waschbisch S Wintterle H Lochmuller MC Walter J Wischhusen BC Kieseier, et al. 2008 Human muscle cells express the costimulatory molecule B7-H3, which modulates muscle-immune interactions Arthritis Rheum 58 11 3600 3608 18975328 10.1002/art.23997 1:CAS:528:DC%2BD1cXhsV2hs7fI
17. M Dastmalchi C Grundtman H Alexanderson CP Mavragani H Einarsdottir SB Helmers, et al. 2008 A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies Ann Rheum Dis 67 12 1670 1677 18272672 10.1136/ard.2007.077974 1:CAS:528: DC%2BD1MXjs1OitA%3D%3D
18. BN Mukunda P Dileep Kumar HR Smith 2001 Long-lasting effectiveness of intravenous immunoglobulin in a patient with inclusion-body myositis Ann Intern Med 134 12 1156 11412071 1:STN:280:DC%2BD3Mzls1ajsQ%3D%3D (Pubitemid 32552211)